Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
- PMID: 19372254
- PMCID: PMC2716019
- DOI: 10.1182/blood-2009-02-206797
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Abstract
Leukocyte (WBC) count has been recently identified as an independent predictor of major thrombosis in both essential thrombocythemia (ET) and polycythemia vera (PV). However, whether leukocytosis should be simply considered a marker for vascular disease or whether elevated WBC levels actually contribute directly to causing such disorders is presently matter of many studies. By adopting epidemiologic criteria for causation, we have examined the characteristics to support this association such as (1) strength, (2) consistency, (3) specificity, (4) temporality, (5) biologic gradient, (6) plausibility, (7) experimental evidence, and (8) analogy. Our conclusion supports the notion that baseline leukocytosis in ET and PV patients adds prognostic significance to existing risk factors and that may be considered causative of vascular events. These developments could induce clinicians to incorporate WBC count into standard clinical practice. However, we need prospective clinical studies with stratification of patients according to their baseline leukocyte counts. Until such evidence is available, the decision on how to manage these patients should continue to follow conventional criteria.
Similar articles
-
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.Thromb Res. 2015 May;135(5):846-51. doi: 10.1016/j.thromres.2015.02.023. Epub 2015 Feb 26. Thromb Res. 2015. PMID: 25743883
-
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.Cancer. 2009 Dec 15;115(24):5740-5. doi: 10.1002/cncr.24664. Cancer. 2009. PMID: 19806641
-
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593. Am J Hematol. 2010. PMID: 20052743
-
Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Eur J Haematol. 2015 Jan;94(1):4-11. doi: 10.1111/ejh.12381. Epub 2014 May 29. Eur J Haematol. 2015. PMID: 24814134 Review.
-
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.Intern Emerg Med. 2010 Jun;5(3):177-84. doi: 10.1007/s11739-009-0319-3. Epub 2009 Sep 30. Intern Emerg Med. 2010. PMID: 19789961 Review.
Cited by
-
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.Blood Cancer J. 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6. Blood Cancer J. 2024. PMID: 39455571 Free PMC article. Review.
-
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.Ann Hematol. 2024 Sep;103(9):3535-3541. doi: 10.1007/s00277-024-05898-3. Epub 2024 Jul 22. Ann Hematol. 2024. PMID: 39037588
-
Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms.Front Cardiovasc Med. 2024 Jun 25;11:1369701. doi: 10.3389/fcvm.2024.1369701. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38984355 Free PMC article.
-
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.J Hematol Oncol. 2024 Jun 9;17(1):43. doi: 10.1186/s13045-024-01562-5. J Hematol Oncol. 2024. PMID: 38853260 Free PMC article.
-
Novel therapeutic strategies for essential thrombocythemia/polycythemia vera.Blood Res. 2023 Apr 30;58(S1):83-89. doi: 10.5045/br.2023.2023013. Blood Res. 2023. PMID: 37105562 Free PMC article. Review.
References
-
- Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–562. - PubMed
-
- Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232. - PubMed
-
- Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353:85–86. - PubMed
-
- Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109:5104–5111. - PubMed
-
- Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–232. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
